Trending Now
The Next Wave for Virus Testing Stocks (HOLX, ALST, FLGT)
While vaccines are rolling out rapidly around the developed world, and uptake is expected to produce some version of herd immunity within...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Cara Therapeutics Inc (NASDAQ:CARA) Reports Topline Results Of Oral KORSUVA In...
Cara Therapeutics Inc (NASDAQ:CARA) posted topline results of Oral Korsuva in a double-blind, randomized, and placebo-controlled clinical study designed to treat Atopic Dermatitis patients...
MAKE IT MODERN
LATEST REVIEWS
Alaunos Therapeutics Inc (NASDAQ: TCRT) Doses Its First Patient in a...
Alaunos Therapeutics Inc (NASDAQ: TCRT) has dosed its first patient in the Phase I/II study. The trial targets EGFR, TP53, and KRAS mutations for...
MAKE IT MODERN
PERFORMANCE TRAINING
GameStop (NYSE:GME) shorts could to be crushed by Apes
GameStop (NYSE:GME) reported a surprise profit in the fiscal fourth quarter, with earnings of 16 cents a share compared to a loss...
Annovis Bio, Inc. (NYSE: ANVS) Surges 24% as Alzheimer’s Treatment Buntanetap Advances to Final Evaluation...
In an exciting development for both the medical community and investors, Annovis Bio, Inc. (NYSE: ANVS), a pioneer in the development...
Cannabis Stocks: Deep Value Opportunity as Legislative Factors Line Up? (CURLF, NUGS, TLRY, SNDL,...
The legislative factor driving the cannabis space in the stock market shouldn’t be underappreciated by long-term investors and speculators alike. The movement...
Galera Therapeutics Inc. (NASDAQ: GRTX) Announced Updated Findings Of Phase 3 ROMAN Study of...
Galera Therapeutics Inc. (NASDAQ: GRTX) has announced that revised findings from the third phase ROMAN study of evasopasem for TY-induced severe oral mucositis treatment...
Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) Announces Its Q3 2020 Financial Results And Provided Clinical Development...
Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) has announced its Q3 2020 financial results and provided business highlights. The company recognized revenue of $48.9 million in Q3...
MAKE IT MODERN
